Journal Article

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Neuberg, Donna, Ross-Macdonald, Petra, Sharpe, Arlene H., Choueiri, Toni K., Hou, Yue, Forman, Juliet, Lichtenstein, Lee, Steinharter, John, Berger, Ashton C., Shukla, Sachet A., Jegede, Opeyemi A., Bakouny, Ziad, Elagina, Liudmilla, Van Allen, Eliezer M., Signoretti, Sabina, Catalano, Paul, Freeman, Gordon J., Braun, David A., Cherniack, Andrew D., Wu, Catherine J., Sant’ Angelo, Miriam, Sun, Maxine, McDermott, David F., Ficial, Miriam, Pignon, Jean-Christophe, Wind-Rotolo, Megan

2020

Overview

PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the immunogenomic determinants of the therapeutic response. Although conventional genomic markers (such as tumor mutation burden and neoantigen load) and the degree of CD8 + T cell infiltration were not associated with clinical response, we discovered numerous chromosomal alterations associated with response or resistance to PD-1 blockade. These advanced ccRCC tumors were highly CD8 + T cell infiltrated, with only 27% having a non-infiltrated phenotype. Our analysis revealed that infiltrated tumors are depleted of favorable PBRM1 mutations and enriched for unfavorable chromosomal losses of 9p21.3, as compared with non-infiltrated tumors, demonstrating how the potential interplay of immunophenotypes with somatic alterations impacts therapeutic efficacy. A pooled genetic, transcriptomic and immunopathologic analysis of over 500 tumors from patients with advanced renal cell cancer suggests that response to PD-1 blockade depends on both CD8 + T cell infiltration and enrichment of tumor-intrinsic somatic alterations.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/67/580 / 692/699/67/1059/2325 / 692/699/67/1059/2326 / 692/699/67/589/1588/1351 / Adult / Aged / Aged, 80 and over / Antigen Presentation - genetics / Antineoplastic Agents, Immunological - therapeutic use / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Carcinoma, Renal Cell - drug therapy / Carcinoma, Renal Cell - genetics / Carcinoma, Renal Cell - immunology / Carcinoma, Renal Cell - pathology / CD8 antigen / CD8-Positive T-Lymphocytes - immunology / CD8-Positive T-Lymphocytes - pathology / Chromosome Deletion / Chromosomes, Human, Pair 6 / Chromosomes, Human, Pair 9 - genetics / Class I Phosphatidylinositol 3-Kinases - genetics / Clear cell-type renal cell carcinoma / Clinical trials / DNA-Binding Proteins - genetics / Exome Sequencing / Female / Fluorescent Antibody Technique / Gene Deletion / Gene sequencing / Genetic analysis / Genomics / Histocompatibility Antigens Class II - genetics / Histone Demethylases - genetics / Histone-Lysine N-Methyltransferase - genetics / Humans / Immune system / Immunofluorescence / Infectious Diseases / Infiltration / Kidney cancer / Kidney Neoplasms - drug therapy / Kidney Neoplasms - genetics / Kidney Neoplasms - immunology / Kidney Neoplasms - pathology / Lymphocytes / Lymphocytes T / Lymphocytes, Tumor-Infiltrating - immunology / Lymphocytes, Tumor-Infiltrating - pathology / Male / Metabolic Diseases / Metastases / Middle Aged / Molecular Medicine / Mutation / Neoantigens / Neurosciences / Nivolumab - therapeutic use / Patients / PD-1 protein / Phenotypes / Prognosis / Proteasome Endopeptidase Complex - genetics / PTEN Phosphohydrolase - genetics / Resistors / Ribonucleic acid / RNA / Sequence Analysis, RNA / TOR Serine-Threonine Kinases - genetics / Transcription Factors - genetics / Transcriptomics / Tuberous Sclerosis Complex 1 Protein - genetics / Tumor Suppressor Proteins - genetics / Tumors / Ubiquitin Thiolesterase - genetics / Von Hippel-Lindau Tumor Suppressor Protein - genetics